Revvity (RVTY) Projected to Post Quarterly Earnings on Monday

Revvity (NYSE:RVTY) is projected to issue its Q4 2025 results before the market opens on Monday, February 2nd. Analysts expect the company to announce earnings of $1.55 per share and revenue of $759.8050 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:00 AM ET.

Revvity Price Performance

Shares of RVTY opened at $108.48 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 1.75. Revvity has a fifty-two week low of $81.36 and a fifty-two week high of $128.04. The firm has a 50-day simple moving average of $103.96 and a 200-day simple moving average of $95.44. The company has a market capitalization of $12.30 billion, a price-to-earnings ratio of 54.51, a price-to-earnings-growth ratio of 3.31 and a beta of 1.05.

Revvity announced that its Board of Directors has authorized a stock buyback program on Monday, October 27th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 8.7% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Shareholders of record on Friday, April 17th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Friday, April 17th. Revvity’s dividend payout ratio (DPR) is presently 14.07%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on RVTY shares. Robert W. Baird upped their price objective on shares of Revvity from $122.00 to $123.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 28th. The Goldman Sachs Group started coverage on shares of Revvity in a research note on Tuesday, December 9th. They set a “neutral” rating and a $105.00 price target on the stock. Wells Fargo & Company raised their price objective on shares of Revvity from $102.00 to $107.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. Barclays lifted their price objective on Revvity from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Guggenheim started coverage on Revvity in a research note on Wednesday, October 15th. They set a “neutral” rating for the company. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Revvity presently has an average rating of “Hold” and a consensus target price of $113.91.

Hedge Funds Weigh In On Revvity

Several hedge funds have recently bought and sold shares of the company. UBS Group AG boosted its position in Revvity by 22.3% during the third quarter. UBS Group AG now owns 2,179,505 shares of the company’s stock worth $191,034,000 after purchasing an additional 397,160 shares in the last quarter. Invesco Ltd. raised its stake in shares of Revvity by 15.7% during the 3rd quarter. Invesco Ltd. now owns 2,553,515 shares of the company’s stock worth $223,816,000 after buying an additional 346,313 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Revvity during the 2nd quarter worth $30,106,000. Bank of America Corp DE boosted its position in shares of Revvity by 40.7% in the 3rd quarter. Bank of America Corp DE now owns 752,567 shares of the company’s stock worth $65,963,000 after buying an additional 217,596 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Revvity by 430.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 256,317 shares of the company’s stock valued at $22,466,000 after acquiring an additional 208,028 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.